Background The transcription factor, WT1, is highly overexpressed in malignant pleural mesothelioma (MPM) and immunohistochemical stains for WT1 are used routinely to aid in its diagnosis. Using computer prediction analysis we designed analog peptides derived from WT1 sequences by substituting amino acids at key HLA-A0201 binding positions. We tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II peptides in patients with thoracic neoplasms expressing WT1. Methods Therapy consisted of six subcutaneous vaccinations administered with Montanide adjuvant on weeks 0, 4, 6, 8, 10, and 12, with 6 additional monthly injections for responding patients. Injection sites were pre-stimulated with GM-CSF (70 mcg). Immune responses were evaluated by DTH, CD4 T-cell proliferation, CD8 T-cell interferon gamma release, intracellular cytokine staining, WT1 peptide MHC-tetramer staining, and cytotoxicity against WT1 positive tumor cells. Results Nine patients with MPM and 3 with NSCLC were vaccinated, with 8 patients receiving at least 6 vaccinations; in total, 10 patients were evaluable for immune response. Six out of nine patients tested demonstrated CD4 T-cell proliferation to WT1 specific peptides, and five of the six HLA-A0201 patients tested mounted a CD8 T-cell response. Stimulated T cells were capable of cytotoxicity against WT-1 positive cells. Vaccination also induced polyfunctional CD8 T cell responses. Conclusions This multivalent WT1 peptide analog vaccine induces immune responses in a high proportion of patients with thoracic malignancies with minimal toxicity. A randomized trial testing this vaccine as adjuvant therapy in MPM is planned.
Introduction
The Wilms' tumor suppressor gene, WT1, was first identified in childhood renal tumors, but it is also highly expressed in multiple other hematologic and solid tumors including mesothelioma [1] [2] [3] [4] [5] . WT1 was originally identified by cDNA mapping to a region of chromosome 11p13. The WT1 cDNA encodes a protein containing four Kruppel zinc fingers and contains a complex pattern of alternative splicing resulting in four different transcription factors. Each WT1 isoform has different DNA binding and transcriptional activities [6] , and can positively or negatively regulate the expression of various genes involved in cellular proliferation, differentiation, apoptosis, organ development and sex determination. WT1 is normally expressed in tissues of mesodermal origin during embryogenesis including the kidney, gonads, heart, mesothelium and spleen [7] . Although originally described as a tumor suppressor gene, the WT1 proteins appear to be involved in tumorigenesis.
The strong expression of WT1 protein in mesothelioma makes it a rational therapeutic target in this disease. The expression is so common that pathologists use immunohistochemical stains for WT1 to help distinguish epithelial mesothelioma from pulmonary adenocarcinoma. In three different pathology series, the rate of WT1 nuclear staining ranged from 72 to 93% [8] [9] [10] . Although WT1 is a nuclear protein, it is processed and presented on the cell surface in the context of MHC molecules [1] . For this reason, WT1 could be targeted using a T cell based immunotherapeutic approach [1] . Indeed, at a National Cancer Institute immunotherapy workshop, WT1 achieved the top priority ranking among potential antigens [11] . Several groups have pursued vaccine strategies against WT1, though these studies have been conducted primarily in patients with myeloid malignancies and none have enrolled patients with mesothelioma [12, 13] .
WT1 protein is a self-antigen, and, as a result, breaking tolerance is necessary for effective vaccination. One strategy to circumvent the poor immunogenicity of tumorassociated peptides is to design synthetic analog peptides that will be more immunogenic. Such ''heteroclitic'' peptides could generate an immune response that recognizes the immunizing epitopes and also cross-reacts with the original native peptides. By using computer prediction analysis, we designed a large number of synthetic peptides derived from WT1 protein sequences in which single or double amino acid substitutions were introduced into the peptides at key HLA A0201 binding positions. Peptides predicted to bind with high affinity to HLA A0201 molecules were directly assayed for their ability to stabilize MHC molecules on the surface of TAP-negative T2 cell line. The new peptides could stabilize MHC molecules better than native sequences. Avidly binding peptides were then assayed in vitro for their ability to elicit HLArestricted, peptide-specific CTL responses using purified T cells from healthy donors. In addition, CD8? T cells stimulated with the new synthetic peptides displayed heteroclitic features and cross-reacted with the native WT1 peptides and also were able to mediate peptide specific cytotoxicity. Importantly, T cells stimulated with the new synthetic peptides were able to kill WT1 expressing, HLA matched CML blasts [14] . In addition, we modified previously identified WT1 peptide segments by adding flanking amino acid segments in order to stimulate the CD4? response necessary for inducing CD8 T-cell memory [15] . These lengthened peptides are recognized in multiple HLA-DRB1 settings. Using cross priming experiments, it was shown that the WT1 peptides are presented on the surface of mesothelioma tumor cells and could be recognized by the T cells stimulated by the individual WT1 DR peptides. Human T cells stimulated with the analog WT1-A1 can kill WT1? mesothelioma cell lines [14, 15] .
In order to broaden immunogenicity over a range of HLA subtypes, we selected four WT1 peptides to combine into a vaccine. The vaccine contains one WT1 heteroclitic peptide to stimulate CD8 responses (WT1-A1), two longer WT1 native peptides to stimulate CD4 responses (WT1-427 long and WT1-331 long) and one longer heteroclitic peptide which could stimulate both CD4 and CD8 cells (WT1-122A1 long). The peptides were combined with Montanide adjuvant before injection, and the injection sites were primed with GM-CSF. We conducted a pilot trial to determine the safety and immunogenicity of the WT1 peptide vaccine in humans. We tested the vaccine in patients with malignant pleural mesothelioma (MPM), and despite the much lower expression rate, also in patients with NSCLC because responses have been reported in a prior WT1 vaccine study [12] .
Patients, materials and methods

Eligibility criteria
The trial was conducted on an FDA-approved IND for a protocol approved by the Institutional Review Board at Memorial Sloan-Kettering Cancer Center. Patients were eligible if they had (1) MPM with unresectable or relapsed disease and had received no more than one prior pemetrexed-containing chemotherapy regimen, or (2) NSCLC, either stage III or IV and completed all initial treatment with surgery and/or chemotherapy and/or radiation therapy. In either case, patients must have had tumors that stained positively for WT1 ([10% of cells). Patients were required to be age C18 years of age and have a Karnofsky Performance Status (KPS) of C70%. Patients were also required to have adequate organ and bone marrow function, including: absolute neutrophil count [1,000/mcL, platelets [50 K/mcL, total bilirubin B2.0 mg/dl, AST and ALT B2.5 9 upper limits of normal, creatinine B2.0 mg/dl. At least 4 weeks must have elapsed between the patient's last chemotherapy or radiation treatment and the first vaccination. Exclusion criteria included pregnant or lactating women, patients with an active infection requiring systemic antibiotics, patients with a serious and unstable medical illness, and patients actively taking corticosteroids. Patients were eligible regardless of HLA haplotype. Patients signed a two-part informed consent, first to allow testing of their tumor sample for WT1 expression, and second to proceed with the WT1 vaccine treatment.
Peptides vaccine preparation and administration:
Peptides used in this study were synthesized by the American Peptide Company (Sunnyvale, CA, USA). The peptides were previously characterized for their binding to MHC molecules and ability to generate human T cell responses in vitro [14, 15] The peptides were 98% pure, sterile and endotoxin free. Each dose of vaccine was prepared by mixing 200 lg of each of the four peptides with equal volume of adjuvant Montanide 51. 200 lg was chosen as the dose because it is within the range of safe and active doses used in other peptide vaccines. Vaccinations were administered subcutaneously with vaccination sites rotated between extremities. Injection sites were pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days -2 and 0.
Treatment plan
Therapy consisted of six vaccinations of the WT1 peptides (1.0 mL of emulsion) administered weeks 0, 4, 6, 8, 10, and 12. Patients who had a clinical response, or who had a molecular or immunologic response without disease progression, were able to continue with up to six more vaccinations administered monthly.
At baseline, all patients had routine blood work, urinalysis, HLA typing, and a CT scan of the chest and other relevant disease sites. Prior to each vaccination and also on week 2, toxicities were recorded, a physical examination was performed, and blood work including a CBC and comprehensive panel was obtained. A follow up CT scan was performed at week 14 (or sooner if deemed medically necessary). Immune responses were measured at baseline, after 3 and 6 vaccinations and at the end of study, using delayed type hypersensitivity (DTH) skin testing and T-cell proliferative response assays (see below).
Evaluation of immunologic responses
Cell lines
The WT1 positive, ALL-derived cell line 697 was kindly provided by Hans J. Stauss (University College London, UK). The WT1 negative B lymphoma cell line SKLY-16 was obtained from the American Type Culture Collection. Both cell lines were HLA-A0201 positive. The cell lines were cultured in RPMI 1640 medium supplemented with 5% FCS, penicillin, streptomycin, 2 mmol/L glutamine, and 2-mercaptoethanol at 37°C, 5% CO 2 . All cells were HLA typed by the Department of Cellular Immunology at Memorial Sloan-Kettering Cancer Center. Expression of WT1 transcripts were determined by quantitative reverse transcription PCR as described earlier [14] .
DTH response
DTH was performed by injecting the peptides (15 mcg per peptide in 70 mL of PBS) intradermally into a marked area the forearm of the patient. A positive control (candida) was injected into a separate site and marked as well. The candida control was only performed at baseline. A positive result was read as redness and induration of [0.5 cm at 24-72 h.
CD4 T cell response
WT1-specific CD4 T cell response was measured by proliferation of the unprimed CD4 T cells against the peptides. In brief, CD4? T cells were purified from PBMC by standard magnetic beads isolation using anti-CD4 mAb (Miltenyi Biotec 
CD8 T cell response
In vitro stimulation
To reliably detect CD8 T cell responses, we performed two rounds of stimulations of CD3 T cells, in vitro. Peripheral blood mononuclear cells (PBMC) from patients were obtained by Ficoll density centrifugation and frozen at -180°C until the samples from all time points were obtained and were tested at the same time. CD14? monocytes were isolated by positive selection using mAb to human CD14 coupled with magnetic beads (Miltenyi Biotec) and part of the cells were used for the first stimulation of T cells at a ratio of 10: 1 (T: APC). The CD14 negative fraction of PBMC was used for isolation of CD3 T cells, by negative immunomagnetic cell separation using a pan T cell isolation kit (Miltenyi Biotec). Purified CD3 T cells were stimulated with immunizing peptides WT1A1, 122A1 or with their native peptides WTA1 and 122A, respectively (20 lg/ml) to expand the WT1A-specific CD8 T cells. The cell cultures were carried out in RPMI 1640 supplemented with 5% autologous plasma, 1 lg/mL b2-microglobulin (b2-M; Sigma), and 10 ng/mL IL-15 (R&D Systems) for 7 days. Monocytederived dendritic cells (DCs) were generated from remaining CD14? cells, by culturing the cells in RPMI 1640 medium supplemented with 1% AP, 500 units/mL recombinant IL-4, and 1,000 units/mL GM-CSF. On days 2 and 4 of incubation, fresh medium with IL-4 and GM-CSF was either added or replaced half of the culture medium. For the 122A or 122A1 cultures, 20 lg/mL 122A or 122A1 peptides were added to the immature DCs on day 5, to allow the processing of the long peptides. Maturation cytokine cocktail (IL-4, GM-CSF, 500 IU/mL IL-1, 1,000 IU/mL IL-6, 10 ng/ml TNF-a, and 1 lg/mL PGE-2), was added to all DC cultures on day 6. On day 7, the mature DCs were used for secondary stimulation of CD3? T cells at a ratio of 1:30, with the same condition for the first stimulation. Seven days later, IFN-c secretion of the cells was examined by enzyme-linked immunospot (ELISPOT) assay and tetramer staining.
IFN-c ELISPOT
Autologous CD14? monocytes (10 4 /well) were incubated with CD3T cells (10 5 cells) for 24 h, in the presence or absence of the testing peptides. All conditions were done in quadruplicate. Phytohemagglutinin (PHA, Sigma) at a concentration of 20 lg/ml was used as a positive control for the assay. Spot numbers were automatically determined with the use of a computer-assisted video image analyzer with KS ELISPOT 4.0 software (Carl Zeiss Vision), as described previously [15] .
Tetramer staining HLA-A0201-PE labeled tetramer loaded with WT1 peptide (RMFPNAPYL) was constructed by the Sloan Kettering Institute tetramer core facility. CD3? T cells after two rounds of stimulations were stained with WT1A/HLA-A0201 tetramer (1:50 dilution) and mAbs against CD3, CD4, CD8 and other T cell markers (CD27, CD28, CD45RA and CCR7), followed by flow cytometry acquisition. Cells were considered positive for tetramer staining when they formed a clear population with mean fluorescence intensity that was at least 1 log above the MHC Class I negative tetramer control (Beckmann Coulter). Events (10 5 ) were collected after live gating on lymphocytes by forward and side scatter. 4 0 ,6-diamidino-2-phenylindole (DAPI, Invitrogen, Carlsbad, CA, USA) was used to gate out dead cells for tetramer staining. Cells were analyzed using a CYAN-ADP flow cytometer with Summit software (Dako Cytomation California Inc., Carpinteria, CA, USA). Analysis was performed using FlowJo software (version 8.1; TreeStar, Inc.).
Chromium-51 cytotoxicity assay
The presence of specific CTLs was measured in a standard 4-h chromium release assay as described [14] . Briefly, target cells are pulsed with 20 lg/mL of synthetic peptides for 2 h at 37°C, after which they are labeled with 50 lCi of Na 2 51 CrO 4 (NEN Life Science Products, Inc.) per one million cells. After extensive washing, target cells are incubated with T cells at various E:T ratios. All conditions were done in triplicate. Plates were incubated for 4 h at 37°C in 5% CO 2 . Supernatant fluids were harvested and radioactivity was measured in a gamma counter. Percentage specific lysis was determined from the following formula: 100 9 [(experimental releasespontaneous release)/(maximum release -spontaneous release)]. Maximum release was determined by lysis of radiolabeled targets in 1% SDS.
Intracellular polyfunctional cytokine staining
CD3? T cells from the same cultures as above were resuspended in 1 ml 10% PHS RPMI medium at a density of 2 million cells/ml. The cells were then stimulated with the addition of peptides for the first 2 h at 37°C and then in the presence of 5 lg/ml each of Brefeldin A and monensin (BD Bioscience) for 4 h. PE-Cy5-CD107a (5 ll/ml BD Pharmingen) was added prior to stimulation. The cells were harvested and washed with 2 ml FACS buffer once. A total of 10 6 cells were resuspended in 50 ll FACS buffer and stained with the following cell surface markers for 30 min at 4°C: Pacific blue-CD3, APC-AF750-CD8 (eBioscience) and ECD-CD4 (Beckman Coulter). After another wash with FACS buffer, the cells were fixed and permeabilized with 100 ll BD Cytofix/Cytoperm solution (BD Bioscience) for 20 min at 4°C, followed by two washes with 19 BD Perm/Wash (BD Bioscience) solution. Finally, the cells were stained with the following cytokine antibodies: PE-MIP-1b, PE-Cy7-TNF-a and FITC-IFN-c (BD Pharmingen). Samples were then acquired on a CYAN flow cytometer. Cell doublets were excluded using forward scatter versus pulsing with parameters. Gating for each cytokine or chemokine was based on a positive control sample stimulated with staphylococcal enterotoxin B (Sigma-Aldrich, St. Louis, MO, USA) and on a negative control sample that was unstimulated. The data analysis program Simplified Presentation of Incredibly Complex Evaluations (SPICE software, version 4.1.6) was used to analyze and generate graphical representations of T cell responses detected by multi-color flow cytometry. All values used for analyzing proportionate representation of responses are background subtracted.
Statistical considerations
The primary endpoints of this pilot study were to evaluate the safety and immunogenicity of the peptide vaccine. We planned to enroll ten evaluable patients with MPM or NSCLC. Patients who completed 8 weeks of the study were considered evaluable. A parallel cohort of patients with myeloid malignancies was also studied in this protocol, and those results will be reported separately.
An immunologic response in six or more out of ten patients would classify this vaccine promising for future study [16] . Clinical and molecular responses were also recorded. Anti-tumor responses were determined based on CT scans using standard RECIST criteria for NSCLC and using modified RECIST criteria [17] for the patients with mesothelioma. Toxicities were tabulated according to the NCI Common Toxicity (version 3.0). If three patients developed Cgrade 3 toxicity felt possibly, likely, or definitely related to the study drug in the opinion of the treating physician, the study was to be closed.
Results
Patient characteristics
39 patients consented to have tumor samples analyzed for WT1 expression by immunohistochemistry, and 32 had evaluable specimens. 8/9 (89%) of the screened MPM tumors had positive staining. Five patients with mesothelioma were enrolled on the treatment portion of the study based on positive WT1 staining evaluated at the time of diagnosis; those samples were not retested. 4/23 (17%) of the NSCLC tumors had positive staining, but it was generally less intense than the MPM samples.
Nine patients with mesothelioma were treated with the WT1 vaccine, and 8 were evaluable for immune response (Table 1) . This included five patients who relapsed after multimodality therapy 14-29 months after completion of therapy; three who had unresectable disease and were previously treated with chemotherapy 4-10 months previously; and one patient who was untreated. All had epithelioid histology. One patient had disease progression after just two injections and was not evaluable for immune response. Three patients with NSCLC were treated, all of whom had stage III disease treated with combined modality therapy which completed 4-7 months before enrollment. One patient withdrew consent after one vaccination, so two patients were evaluable for immune response.
Safety and toxicity
Seven of the 12 patients experienced grade 1 injection site reactions which included swelling, redness or pruritus. No other toxicities attributable to the vaccine were noted, and specifically no pulmonary, renal, or hematologic toxicities.
Induction of DTH responses
Two out of 7 patients with MPM that were tested for DTH developed a response. The 3 other patients with MPM were unable to be tested. One out of 2 NSCLC patients tested had a DTH positive reaction.
Vaccination induces WT1-specific CD4 T cell response CD4 T cell response to immunizing WT1 peptides 331, 427 and 122A1 and the native peptide 122A was directly assessed by unprimed CD4? T cell proliferation. A total of nine patients were tested after 3 or 6 vaccinations: seven patients were tested at both timepoints, and patients 9 and 11 were tested only after 3 vaccinations, as summarized in Fig. 1a . Prior to vaccination, none of patients showed any peptide-specific responses. The small response to 331, 427 or 122A1 seen in patient 1 on time 0 was not significant statistically (p = 0.24, 0.28 or 0.16, respectively). Following vaccinations, six patients (# 4, 6, 8, 10, 11 and 12) showed significantly increased proliferation to the immunizing peptides (defined as an increase of more than twice the stimulation index SI: counts per minute in the test sample divided by counts per minute in the control and a p \ 0.05). Three patients (# 1, 3 and 9) did not have measurable responses to any of the peptides tested. Four patients responded to peptide 331, five patients responded to 427, and 4 patients responded to 122A1 peptides. (There were not enough cells for patient 11 to test all the peptides, and therefore, peptide 122A1 was not tested). Among the peptides tested, WT1-331 seemed to be the most immunogenic, as shown by 4 out of 6 patients who had strong responses to the peptide. Two of five patients who responded to 122A1 also showed a weak response to its native peptide 122A (data not shown). As an example of a typical raw data set, detailed data of the CD4 T cell proliferation from patient 10 are shown in Fig. 1b . After 3 vaccinations, at concentrations of 20 or 50 lg/ml peptides tested, CD4 T cell proliferation increased 47.5-and 39.4-fold to 331; 37.4-and 10.8-fold increase to 427 and 2.7-fold to 122A1, respectively (middle panel). Similar responses were also detected after six vaccinations (lower panel).
Vaccination induces WT1-specific CD8 T cell responses
CD8 T cell response specific for the epitope WT1-A was measured by IFN-c secretion, frequency of the WT1-A/ HLA-A0201 tetramer positive cells and cytotoxicity against the WT1? tumor cells. Evaluable patients who were HLA-A0201 positive were tested for their CD8 T cell response to HLA-A0201-restricted peptide WT1-A1 and WT1-A by IFN-c ELISPOT assay (n = 5) and WT1-Aspecific tetramer staining (n = 6). To reliably detect the peptide-specific response, CD3? T cells were stimulated with immunizing peptides and their native sequences in vitro for two rounds to expand the frequency of the cells. A positive response to the vaccine was defined as a twofold increase in IFN-c-secreting cells and in frequencies of CD8? WT1-A tetramer? cells, over the controls (irrelevant peptides), with at least 30 spots and p \ 0.05. The IFN-c secretion from the five patients was summarized as the fold-increase over the control peptide for the time point before and after 3 and 6 vaccinations (Fig. 2a) and in more detail for patient #1 for the post 9 and 12 vaccination time points (Fig. 2b) . CD3 T cells were stimulated with analog peptide WT1-A1 and were tested against its native peptide WT1-A. Prior to vaccination, only one patient (#4) showed significant IFN-c secretion by CD3 T cells specific for WT1-A peptide (50 times over the There was no response in patient #1 after 3 and 6 vaccinations; however, after 9 and 12 vaccinations, the response to the WT1-A native sequence increased threefold after WT1-A and WT1-A1 stimulation (Fig. 2b) .
IFN-c secretion increased twofold for patient #3 after 6 vaccinations (p 0.014); however, the increase was not significant compared to the pre-vaccination 1.4-fold increase over the control peptide.
Patient #4 had very strong pre-existing WT1-A-specific ELISPOT response and no further increase in IFN-c secretion was induced after 3 or 6 vaccinations, although there were 29-and 47-fold increases over the control peptide at the above time points.
A strong response was seen for patient #8 after 3 vaccinations, with a 43-fold increase in IFN-c secretion over the control. Unfortunately, there were not enough cells after 6 vaccinations to test the duration of response.
The strongest response was observed in patient 12, with a 262-fold increase in IFN-c secretion specific for WT1-A peptide over the control, after 6 vaccinations. A similar response was also seen in the cultures when T cells were stimulated with the native WT1-A peptide (data not shown).
The frequency of WT1-A/HLA-A0201 tetramer positive CD8 T cells increased as early as after 3 vaccinations in 3 patients (#4, #8, #12) who also had increased IFN-c secretion (Fig. 3a) . No increase in tetramer positive populations was detected in patients 1, 3 and 11 (not shown). A detailed analysis on WT1-A/HLA-A0201 tetramer staining from patient #4 is illustrated (Fig. 3b) . Stimulating CD3 T cells with the analog peptide WT1-A1 would demonstrate the cross-reactivity between the analog and its native peptides; stimulating T cells with longer peptides 122A or 122A1 would address the question of the processing and the presentation of the WT1-A epitope. Percentages of WT1-A/HLA-A0201 tetramer positive CD8 T cells from pre-, and after 3 and 6 vaccinations are shown as T0, T3 and T6. Prior to vaccination, WT1-specific T cells comprised 1.17% of CD8 T cells, in response to WT1-A peptide stimulation. The percentage of the tetramer positive cells in this culture is much higher than the stimulation with other peptides WT1-A1, 122A and 122A1, suggesting that the WT1-specific precursor CD8 T cells existed and expanded efficiently when the native peptide was used for the stimulation. Following vaccination, a robust increase in WT1-A specific CD8 T cells was seen in all cultures with indicated peptide stimulations. Of note is that with WT1-A1 analog peptide stimulation, the percentage of WT1-Aspecific CD8 T cells steadily increased from 0.11 to 2.47% and 4.36%, after 3 and 6 vaccinations. This result demonstrated vaccination of patients with analog peptide WT1-A1 elicited an efficient CD8 T cell response against the native sequence (i.e. a heteroclitic response). Interestingly, stimulating cells with 122A1 class II analog peptide induced WT1-specific CD8 T cell responses, in a similar magnitude as did class I analog peptide WT1-A1, demonstrating efficient processing, presentation of, and cross reactivity to the WT1-A epitope in vitro.
In addition, we measured the cytotoxicity in patients who had sufficient CD3 T cells. T cells were defrosted and re-stimulated with autologous DCs, CD14? cells, or CD40L-activated B cells [18] and cytotoxicity was measured against the WT1 positive cell line, 697, or WT1-negative cell line, SKLY-16. Both cell lines were HLA-A0201-positive and have been well defined in our previous studies as suitable to test HLA-A0201-restricted, WT-1-specific killing by stimulated T cells [14, 15] . Cytotoxicity was not observed with cells obtained before (Fig. 4a, patient #8 ). We also detected the similar WT1-specific cytotoxicity in patient #3 after 3 and 6 vaccinations and patient #4 after 9 vaccinations (cells from other time points were not available) (Fig. 4b) . These results demonstrated that the vaccinations were able to elicit a WT1-specific, HLA-A0201-restricted cytotoxic CD8 T cell response.
WT1-specific CD8 T cell responses are polyfunctional
The quality of T cell response is a crucial factor in defining a protective T cell response. The frequency of IFN-c-producing T cells has been the most widely used parameter to assess vaccine-induced T cell response. However, the magnitude of a T cell response measured by a single parameter does not always reflect its full functional potential. Recent studies in infectious diseases have used multiparameter flow cytometry to characterize the quality of the T cell response. These studies provided compelling evidence that cytokine-producing profiles could define distinct populations of T cells, and T cells that are able to produce multiple cytokines (polyfunctional T cell response) correlate with improved protection against viral infection [19] . Similarly, an effective cancer vaccine should also be able to elicit this type of response. For example, a phase I/II trial of human GM-CSF DNA in conjunction with a multipeptide vaccine (gp100 and tyrosinase) in stage III/IV melanoma patients showed polyfunctional CD8? T cell response to the gp100 peptide [20] .
We evaluated if the WT1 peptide vaccination could induce such polyfunctional T cell responses. CD3 T cell were challenged with CD8 epitope WT1-A, its analog WT1-A1 or irrelevant peptide EW. The expression of the surface CD107a (marker for mobilization of degranulation), 
Discussion
WT1 is a nuclear protein that regulates the expression of several genes involved in tumor growth. Because it is processed and presented in the context of MHC molecules on the cell surface, WT1 has potential as a target for T cell therapies. Several groups are pursuing this strategy. Oka and colleagues in Japan conducted a Phase I clinical study of immunotherapy targeting a different WT1 class 1 peptide in patients with leukemia, MDS, lung cancer, or breast cancer [12] . Patients were intradermally injected with an HLA-A*2402-restricted, native, or modified 9-mer WT1 peptide emulsified with Montanide ISA51 VG UFCH adjuvant at 0.3, 1.0, or 3.0 mg per body at 2-week intervals, with toxicity and clinical and immunological responses as the principal endpoints. Twenty-six patients received one or more WT1 vaccinations, and 18 of the 26 patients completed WT1 vaccination protocol with three or more injections of WT1 peptides. Twelve of the 20 patients for whom the efficacy of WT1 vaccination could be assessed showed clinical responses such as reduction in leukemic blast cells or tumor sizes and/or tumor markers. A clear correlation was observed between an increase in the frequencies of WT1-specific cytotoxic T lymphocytes after [13] . Interestingly, they detected IgM and IgG responses to WT1 in about 15% of patients before treatment. The vaccine augmented IgM responses in 6 of 6 patients at week 26 or 30, though no CD4 T-cell or IgG responses were noted [21] . WT1 tetramer? Tcells increased in the blood or bone marrow in 45% of cases. Anti-tumor activity was noted in several patients, primarily with prolonged stable disease and some hematologic improvement, but remarkably one patient with secondary AML achieved a complete cytogenetic response. A threefold decrease in WT1 mRNA levels was noted in 35% of patients. In both the Japanese and German studies, toxicity was essentially limited to injection site reactions. At the NIH, a combined vaccine of two leukemia-associated antigenic peptides, PR1 and WT1 was tested in eight patients with myeloid neoplasms [22] . After vaccination, PR1 or WT1(?)CD8(?) T cell responses were associated with drops in WT1 mRNA expression, suggesting an antileukemia effect of vaccination. We have also observed robust CD4 and CD8 T-cell immune responses to WT1 peptides in patients with AML vaccinated in the companion part of this trial (Maslak et al., submitted). Ongoing studies of WT1 immune-directed therapy are being conducted by Moffit Cancer Center, Duke University, and Glaxo-Smith Kline (http://www.clinicaltrials.gov).
In comparison to these other studies, ours has several unique aspects. Foremost, this is the first study that included patients with mesothelioma, a disease known to have high expression of WT1 and therefore an optimal target population. Furthermore, we are the first to target multiple epitopes and both CD4 and CD8 WT1 epitopes simultaneously. We utilized a multivalent vaccine that included four different WT1 peptides that were designed to elicit both CD4 and CD8 T cells, across a broad range of HLA subtypes [15] . In addition, heteroclitic analogs of the CD8 epitope were used to enhance the immune response to the WT1 self-protein, to which many patients might be tolerant. By using an altered amino acid sequence not found in the native sequence, but which bound with higher affinity to the HLA-A0201, we postulated that a stronger immune response could be generated and that this response would cross react with the native sequence.
This response was observed after vaccination in the trial. We observed a high rate of both CD8 and CD4 immune responses to the vaccine. CD4 T cell responses did not correlate with particular HLA-DR types, suggesting that such promiscuous peptides [15] could prime CD4 T cell responses in a broader range of patients, compared to the WT1 peptides that have been reported to date. The vaccination also induced polyfunctional CD8 T cell responses in the patients tested, suggesting a broader repertoire of T cell response could be elicited. Other studies have suggested that CD8? T cells that secrete both IFN-c and TNF-a have enhanced cytolytic activity compared with CD8? T cells that secret IFN-c alone [23, 24] . Therefore, analyzing such polyfunctional T cell responses might be insightful for understanding the mechanisms underlying vaccine efficacy for the future cancer vaccine studies. We also examined whether a long peptide designed to elicit CD4 responses (122-A1) containing a cryptic CD8 analog epitope buried within it (WT1-A1) could generate an appropriate responses in vitro to the CD8 native epitope. CD8 ELI-SPOT and tetramer staining studies confirmed that this was the case.
Conclusions about therapeutic activity of this vaccine are difficult to surmise, particularly in patients with MPM. This is a heterogenous patient population-half had relapsed disease after prior multimodality therapy including surgery, and half had unresectable disease, most of whom had received chemotherapy-making predictions of expected outcomes difficult. Two prior studies provide some guidance: (1) In a multicenter trial of trimodality therapy for MPM, the median time to progression was 10 months and the median survival was 16 months [25] , and (2) In the phase III trial of pemetrexed and cisplatin, the median survival from the onset of chemotherapy was 12 months [26] . Thus, the median survival of 14 months in this study, which is measured from the initiation of vaccination, is encouraging. Of particular interest is the one patient who has not demonstrated disease progression 3 years after initiating the vaccine program. Nonetheless, this is a highly selected patient population and a small sample size. Similarly encouraging outcomes were noted in a parallel trial in which patients with acute myelogenous leukemia were vaccinated with the same WT1 peptides (Maslak, manuscript in press). As in the other WT1 peptide vaccine studies, toxicity was mostly grade one and limited to local injection site reactions. The lack of significant toxicity becomes important for this group of patients who are generally older and frail due to their disease. Based on these findings we have designed a randomized phase II trial in patients comparing treatment with our WT1 vaccine to treatment with adjuvant alone in patients with resected MPM to determine if clinical benefit can be measured. This overall approach of a pilot trial followed by a randomized phase II study conforms with a paradigm established by Cancer Vaccine Clinical Trial Working Group [27] . Incorporation of the WT1 vaccine in conjunction with chemotherapy for patients with advanced disease may be another valid approach to pursue.
